scholarly journals Significant elevation of aqueous endothelin-1 in central retinal vein occlusion

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252530
Author(s):  
Hae Min Kang ◽  
Md. Hasanuzzaman ◽  
So Won Kim ◽  
Hyoung Jun Koh ◽  
Sung Chul Lee
Keyword(s):  
Retinal Vein Occlusion ◽  
Aqueous Humor ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Control Group ◽  
Endothelin 1 ◽  
Intravitreal Bevacizumab Injection ◽  
Vein Occlusion ◽  
The Mean ◽  
Central Retinal Vein

Purpose To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group. Methods A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month. Results At baseline, the mean aqueous ET-1 level was 12.7±3.6 pg/mL in the CRVO group, 8.0±2.3 pg/mL in the BRVO group, and 2.0±0.9 pg/mL in the control group (P<0.001). After IVB, the mean aqueous level of ET-1 was 3.4±1.9 pg/mL (0.5–6.9 pg/mL) in the CRVO group and 1.8±1.0 pg/mL (0.3–3.2 pg/mL) in the BRVO group (P = 0.008). The mean aqueous ET-1 level was significantly reduced in both the patients with CRVO and those with BRVO (P<0.001). Conclusion The mean aqueous humor ET-1 level was significant higher in the patients with CRVO than those with BRVO and in the control group. After IVB, the mean level was significantly reduced in both the patients with CRVO and those with BRVO.

scholarly journals Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy

2021 ◽  
Vol 6 (1) ◽  
pp. e000728
Author(s):  
Ian L McAllister ◽  
Lynne A Smithies ◽  
Fred K Chen ◽  
David A Mackey ◽  
Paul G Sanfilippo
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Diastolic Pressure ◽  
Venous Pressure ◽  
Control Group ◽  
Vein Occlusion ◽  
Registration Number ◽  
Chorioretinal Anastomosis ◽  
The Mean ◽  
Central Retinal Vein

ObjectiveTo evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compared with ranibizumab monotherapy.Methods and AnalysisThis is a post-hoc analysis of the 2-year randomised ranibizumab plus L-CRA for CRVO trial. Twenty-four patients (82.5%) developed a functioning or successful L-CRA; outcome effects were monitored in the monthly as-needed ranibizumab phase from months 7 to 24 and compared with the ranibizumab monotherapy group (n=29).ResultsFrom months 7 to 24, the mean (95% CI) injection load for the functioning L-CRA group was 2.18 (1.57 to 2.78) compared with 7.07 (6.08 to 8.06) for the control group (p<0.0001). The mean BCVA was averaged across all timepoints between the control and functioning L-CRA groups (average difference=11.46 (3.16 to 19.75) letters, p=0.01). At 2 years, there was an 82.5% reduction in the odds of high CVP (greater or equal to central retinal artery diastolic pressure) for those with a successful L-CRA compared with controls (p<0.0001).ConclusionFor patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864.

scholarly journals Central retinal vein occlusion associated with platelet activation

2019 ◽  
Vol 11 ◽  
pp. 251584141986484 ◽  
Author(s):  
Mehmet Citirik
Keyword(s):  
Retinal Vein Occlusion ◽  
Platelet Activation ◽  
Central Retinal Vein Occlusion ◽  
Mean Platelet Volume ◽  
Control Group ◽  
Platelet Distribution Width ◽  
Platelet Volume ◽  
Distribution Width ◽  
Vein Occlusion ◽  
Central Retinal Vein

Purpose:The aim of this article is to determine and compare the platelet activation by three main platelet activation parameters: mean platelet volume, platelet distribution width, and plateletcrit in patients with central retinal vein occlusion and control subjects.Methods:This study included 30 patients with nonischemic central retinal vein occlusion and 30 control subjects. The levels of mean platelet volume, platelet distribution width, and plateletcrit were measured in all groups.Results:The mean serum level of mean platelet volume was 10.01 ± 0.89 fl in central retinal vein occlusion group and 8.74 ± 1.45 fl in control group. The mean serum level of platelet distribution width was 14.31 ± 1.49% and 11.65 ± 1.81% in central retinal vein occlusion group and control group, respectively. Mean serum plateletcrit value was 0.27 ± 0.07% in central retinal vein occlusion group and 0.23 ± 0.07% in control group. Mean platelet volume, platelet distribution width, and plateletcrit levels were significantly higher in central retinal vein occlusion patients than controls ( p < 0.05).Conclusion:Subclinical platelet activation reflected by mean platelet volume, platelet distribution width, and plateletcrit may have an impact on the genesis of vessel occlusion in central retinal vein occlusion. The results may be important for the clinical management of patients with central retinal vein occlusion.

Sign in / Sign up

Export Citation Format

Share Document